NEW YORK, NY / ACCESSWIRE / February 1, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Boston Scientific Corporation (NYSE:BSX)
Class Period: April 24, 2019 - November 16, 2020
Lead Plaintiff Deadline: February 2, 2021
The BSX lawsuit alleges that Boston Scientific Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) the LOTUS Edge Aortic Valve System's product delivery system was dysfunctional and threatened the continued viability of the entire product line; (ii) as a result, the Company had materially overstated the continued commercial viability and profitability of the LOTUS Edge Aortic Valve System; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in BSX: http://www.kleinstocklaw.com/pslra-1/boston-scientific-corporation-loss-submission-form-2?id=12569&from=1
GoodRx Holdings, Inc (NASDAQ:GDRX)
Class Period: September 23, 2020 - November 16, 2020
Lead Plaintiff Deadline: February 16, 2021
GoodRx Holdings, Inc allegedly made materially false and/or misleading statements and/or failed to disclose that: at the time of the IPO, unbeknownst to investors, Amazon.com, Inc. was developing and would soon introduce its own online and mobile prescription medication ordering and fulfillment service that would directly compete with GoodRx. Defendants timed the IPO so that it was priced before Amazon announced its online pharmaceutical business to facilitate the IPO and create artificial demand for the common shares sold therein, as well to maximize the amount of money the Company and the selling stockholders could raise in the IPO. Given defendants' knowledge of Amazon's intention to enter the online pharmaceutical business, and their misleading statements about GoodRx's competitive position made contemporaneously with that knowledge, defendants' materially false and/or misleading statements alleged herein were made willfully and caused GoodRx common stock to trade at artificially inflated prices during the Class Period.
Learn about your recoverable losses in GDRX: http://www.kleinstocklaw.com/pslra-1/goodrx-holdings-inc-loss-submission-form?id=12569&from=1
9F Inc. (NASDAQ:JFU)
Lawsuit on behalf of investors who purchased JFU securities: (1) pursuant and/or traceable to the registration statement and related prospectus issued in connection with the Company's August 14, 2019 initial public offering; and/or (2) between August 14, 2019 and September 29, 2020.
Lead Plaintiff Deadline: March 22, 2021
During the class period, 9F Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the purported value and benefits of the Company's financial institution partners and its tri-party cooperation business model did not in fact exist and/or were materially overstated, given that 9F and Property and Casualty Company Limited ("PICC") had been engaged in an ongoing contractual dispute regarding payment of service fees under their cooperation agreement; (2) the collectability of service fees owed to 9F by PICC under the cooperation agreement was in doubt and at serious risk of non-payment; (3) there was a significant risk that PICC would no longer provide credit insurance and guarantee protection to investors and institutional funding partners; (4) as a result of the foregoing, the Company's platform, business model, reputation and financial results had been materially impaired; and (5) as a result, Defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Learn about your recoverable losses in JFU: http://www.kleinstocklaw.com/pslra-1/9f-inc-loss-submission-form?id=12569&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm